FOXA1: a Promising Prognostic Marker in Breast Cancer |
Hu, Qing
(Department of General Surgery, Xuzhou Medical College)
Luo, Zhou (Department of Oncology, Nanjing Medical University) Xu, Tao (Department of Oncology, Nanjing Medical University) Zhang, Jun-Ying (Department of Oncology, Xuzhou Medical College) Zhu, Ying (Department of Oncology, Nanjing Medical University) Chen, Wei-Xian (Department of Oncology, Nanjing Medical University) Zhong, Shan-Liang (Clinical Laboratory Center) Zhao, Jian-Hua (Clinical Laboratory Center) Tang, Jin-Hai (Department of General Surgery, Jiangsu Cancer Hospital) |
1 | Nakshatri H, Badve S (2007). FOXA1 as a therapeutic target for breast cancer. Expert Opin Ther Targets, 11, 507-14. DOI ScienceOn |
2 | Liu N, Niu Y, Wang SL, et al (2010). Diagnostic and prognostic sign ificance of FOXA1 expression in molecular subtypes of breast invasive ductal carcinomas. Zhonghua Yi Xue Za Zhi, 90, 1403-7. |
3 | Mehta RJ, Jain RK, Leung S, et al (2012). FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Res Treat, 131, 881-90. DOI ScienceOn |
4 | Perou CM, Sorlie T, Eisen MB, et al (2000). Molecular portraits of human breast tumours. Nature, 406, 747-52. DOI ScienceOn |
5 | Sircoulomb F, Bekhouche I, Finetti P, et al (2010). Genome profiling of ERBB2-amplified breast cancers. BMC Cancer, 10, 539. DOI ScienceOn |
6 | Sorlie T, Perou CM, Tibshirani R, et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A, 98, 10869-10874. DOI ScienceOn |
7 | Thorat MA, Marchio C, Morimiya A, et al (2007). Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. J Clin Pathol, 61, 327-32.. DOI ScienceOn |
8 | Wolf I, Bose S, Williamson EA, et al (2007). FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer. Int J Cancer, 120, 1013-22. |
9 | Yamaguchi N, Ito E, Azuma S, et al (2008). FoxA1 as a lineagespecific oncogene in luminal type breast cancer. Biochem Biophys Res Commun, 365, 711-7. DOI ScienceOn |
10 | Yerushalmi R, Woods R, Ravdin PM, et al (2010). Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol, 11, 174-83. DOI ScienceOn |
11 | Habashy HO, Powe DG, Rakha EA, et al (2008). Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. Eur J Cancer, 44,1541-51. DOI ScienceOn |
12 | Costa RH, Grayson DR, Darnell JE, et al (1989). Multiple hepatocyte-enriched nuclear factors function in the regulation of transthyretin and alpha 1-antitrypsin genes. Mol Cell Biol, 9, 1415-25. |
13 | Desantis C, Ma J, Bryan L, et al (2013). Breast cancer statistics. CA Cancer J Clin, 9, 69-90. |
14 | Goldhirsch A, Ingle JN, Gelber RD, et al (2009). Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol, 20, 1319-29. DOI ScienceOn |
15 | Hayes DF (2005). Prognostic and predictive factors revisited. Breast, 14, 493-9. DOI ScienceOn |
16 | Hisamatsu Y, Tokunaga E, Yamashita N, et al (2012). Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer. Ann Surg Oncol, 19, 1145-52. DOI ScienceOn |
17 | Kim C, Paik S 2010. Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol, 7, 340-7. DOI |
18 | Hurtado A, Holmes KA, Ross-Innes CS, et al (2011). FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet, 43, 27-33. DOI ScienceOn |
19 | Ijichi N, Shigekawa T, Ikeda K, et al (2012). Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients. Horm Cancer, 3, 147-59. DOI ScienceOn |
20 | Kawase M, Toyama T, Takahashi S, et al (2013). FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer. Breast Cancer. [Epub ahead of print] |
21 | Knight WA, Osborne CK, Yochmowitz MG, et al (1980). Steroid hormone receptors in the management of human breast cancer. Ann Clin Res, 12, 202-7. |
22 | Badve S, Turbin D, Thorat MA, et al (2007). FOXA1 expression in breast cancer--correlation with luminal subtype A and survival. Clin Cancer Res, 13, 4415-21. DOI ScienceOn |
23 | Ademuyiwa FO, Thorat MA, Jain RK, et al (2010). Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. Mod Pathol, 23, 270-5. DOI ScienceOn |
24 | Albergaria A, Paredes J, Sousa B, et al (2009). Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. Breast Cancer Res, 11, R40. DOI ScienceOn |
25 | Badve S, Nakshatri H (2009). Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. J Clin Pathol, 62, 6-12. DOI ScienceOn |
26 | Carroll JS, Brown M (2006). Estrogen receptor target gene: an evolving concept. Mol Endocrinol, 20, 1707-14. DOI ScienceOn |
27 | Beck S, Sommer P, dos Santos Silva E, et al (1999). Hepatocyte nuclear factor 3 (winged helix domain) activates trefoil factor gene TFF1 through a binding motif adjacent to the TATAA box. DNA Cell Biol, 18, 157-64. DOI ScienceOn |
28 | Bernardo GM, Keri RA (2012). FOXA1: a transcription factor with parallel functions in development and cancer. Biosci Rep, 32, 113-30. DOI ScienceOn |
29 | Bernardo GM, Lozada KL, Miedler JD, et al (2010). FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis. Development, 137, 2045-54. DOI ScienceOn |
30 | Kouros-Mehr H, Slorach EM, Sternlicht MD, et al (2006). GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell, 127, 1041-55. DOI ScienceOn |